ReviewJournal of clinical medicine2021
Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Morphea En Coup De Sabre Treated With Combination Hyaluronic Acid Filler and Neuromodulator: A Case Report.Cureus · 2026Article
- Long-term follow-up of linear scleroderma en coup de sabre in children with central nervous system involvement.Frontiers in immunology · 2026Article
- Alopecia areata.Nature reviews. Disease primers · 2025Review
- Plastic Surgery Interventions for Localized Scleroderma Deformities: an Evidence Synthesis.Aesthetic plastic surgery · 2025Review
- Bilateral morphea en coup de sabre following onabotulinum toxin A injections.JAAD case reports · 2025Article
- Autologous adipose tissue transfer in progressive hemifacial atrophy: From simple volume to regenerative cell therapy.JPRAS open · 2025Review
- Development of Coup de Sabre in an HIV-Positive Patient: A Case Study from Lilongwe, Malawi.The American journal of tropical medicine and hygiene · 2025Article
- Article
- Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications.Toxins · 2025Review
- Combination of Oral Hydroxychloroquine and Topical Pimecrolimus 1% for Linear Morphea in Breastfeeding: A Rare Case with Favorable Outcome.International journal of women's health · 2025Article
- Dacryoadenitis associated with linear sclerodermaSkin health and disease · 2024Article
- [Localized scleroderma].Dermatologie (Heidelberg, Germany) · 2024Review
- Disturbances of the stomatognathic system and possibilities of its correction in patients with craniofacial morphea.Postepy dermatologii i alergologii · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleroderma (morphea) en coup de sabre is a localized subtype restricted to the frontoparietal region of the head. Current treatment paradigms rely on low levels of evidence, primarily case reports and case series-supported by expert opinions. The aim of this article was to systematically analyze current data related to the treatment of localized scleroderma en coup de sabre. The databases Scopus, PubMed, and EBSCO were searched for all reports discussing the treatment of localized scleroderma en coup de sabre. The keywords en coup de sabre, "facial linear scleroderma", and "morphea linearis", combined with "treatment" or "therapy" were used as search terms. A total of 34 articles analyzed treatment outcomes for patients with localized scleroderma en coup de sabre including 4 retrospective cohort studies, 2 prospective cohort studies, 4 case series, and 24 case reports, representing a total of 69 patients (38 children and 31 adults). Methotrexate was the most commonly investigated treatment (26 patients) with a highest response rate (26/26, 100%). Other treatments included systemic glucocorticosteroids (nine patients), followed by UVA1 (four patients), mycophenolate mofetil (two patients), hydroxychloroquine (five patients), abatacept (two patients), tocilizumab (three patients), cyclosporine (one patient), interferon gamma (one patient), PUVA therapy (two patients), NB-UVB therapy (one patient), and pulsed dye laser (one patient). Reconstructive and surgery treatment was successfully used for lesions with settled disease activity to improve the cosmetic aspect of the lesions. Conclusion: methotrexate is the most often-studied treatment and reported good clinical outcomes in children and adults with localized scleroderma en coup de sabre.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.